$7.30
Value $1.8B
BCRX and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$7.30
Value $1.8B
$137.78
Value $341B
BioCryst Pharmaceuticals (BCRX) has a market value of $1.8B and Merck & Company (MRK) $341B. Over the last year, with dividends, BCRX moved +3.8% and MRK +52.7%. Dividend yield: BCRX none, MRK 2.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
BCRX$1.8B
MRK$341B
MRK is 186 times BCRX
Revenue, 12 months
BCRX$962M
MRK$67.4B
MRK is 70 times BCRX
Net income, 12 months
BCRX-$360M
MRK$2.5B
Operating margin
BCRX-30.1%
MRK–
ROIC
BCRX–
MRK3.9%
P/E
BCRX–
MRK138.9
Dividend yield
BCRX0.0%
MRK2.5%
2.5 points apart
5-year return
BCRX-39.2%
MRK+94.3%
133.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
BCRX-39.2%
MRK+94.3%
| Period | BCRXWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +3.8%Price +3.8% | +52.7%Price +48.4% |
| 3 years since November 17, 2023 | +36.4%+10.9% a yearPrice +36.4% | +48.4%+14.1% a yearPrice +35.4% |
| 5 years since November 17, 2021 | -39.2%-9.5% a yearPrice -39.2% | +94.3%+14.2% a yearPrice +66.8% |
| 10 years since November 18, 2016 | +22.1%+2.0% a yearPrice +22.1% | +216.6%+12.2% a yearPrice +133.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
BCRXBioCryst PharmaceuticalsMRKMerck & Company
| Price | $7.30 | $137.78 |
|---|---|---|
| Market value | $1.8B | $341B |
| Enterprise value (EV) | – | $385B |
| P/E | – | 138.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | – | 7.6 |
| EV/EBIT | – | 80.8 |
| Free cash flow yield | 20.0% | 4.3% |
| Revenue, 12 months | $962M | $67.4B |
|---|---|---|
| Net income, 12 months | -$360M | $2.5B |
| Free cash flow, 12 months | $366M | $14.7B |
| Earnings per share, 12 months | -$1.41 | $0.98 |
| Revenue growth, year on year | 94.1% | 1.3% |
| Revenue growth a year, past | +117.9%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | 97.9% | 71.8% |
|---|---|---|
| Operating margin | -30.1% | – |
| Net margin | -37.4% | 3.6% |
| ROIC | – | 3.9% |
| ROE | – | 5.2% |
| Cash | $375M | $9.7B |
|---|---|---|
| Total debt | – | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | -3.8× | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.5% |
| Shareholder yield | – | 4.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($341B) is about 186.1 times BioCryst Pharmaceuticals ($1.8B), at today's prices.
Since November 18, 2016, BCRX's price moved +22.1% and MRK's +133.4%. With dividends: BCRX +22.1% (+2.0% a year), MRK +216.6% (+12.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for BioCryst Pharmaceuticals and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
Over the last twelve months, the net margin was -37.4% for BioCryst Pharmaceuticals and 3.6% for Merck & Company, and the operating margin -30.1% and –. Revenue was $962M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.